固尔舒与沐舒坦预防早产儿呼吸窘迫综合征的临床研究

目的:探讨沐舒坦和固尔舒对早产儿呼吸窘迫综合征(RDS)的预防作用。方法:将100例早产儿随机分为三组:A组(17例)出生后经气道给予固尔舒100~150 mg/kg;B组(39例)经静脉给予沐舒坦15~20 mg/kg,每2 h给药一次,共2次;C组(44例)给予一般综合治疗。结果:A组发生RDS者1例,无死亡病例。B组发生RDS者7例,死亡2例。C组发生RDS者15例,死亡6例。三组早产儿的RDS发生率比较,具有显著性差异(2χ=55.59,P<0.01);但死亡率比较,无显著性差异(2χ=3.81,P>0.05)。结论:对母亲产前未使用皮质激素的早产儿出生后立即静脉给予沐舒坦或经气道给予固尔舒可以较好的预防呼吸窘迫综合征及其并发症的发生。

Preventive effect of mucosolvan or curosurf on neonatal respiratory distress syndrome.

Objective:To investigate the preventive effect of mucosolvan or curosurf on premature infants respiratory distress syndrome.Methods:100 premature infants were divided into three groups:group A(17 cases) child bearing was given by windpipe after curosurf;group B(39 cases) was given by vein the mucosolvan;and group C(44 cases) was given synthesized treatment.Results:The A group had 1 case of respiratory distress syndrome(RDS) and no case of the death.That B group had 7 cases of RDS and 2 deaths.C group had 15 cases of RDS and 6 deaths.The RDS rate among three groups had significant difference(χ2=55.59,P<0.01);but the rate of death had no obvious difference(χ2=3.81,P>0.05).Conclusion:It is valuable to administer mucosolvan by vein or give curosurf by windpipe to premature infants immediately after birth in order to reduce the incidence of RDS and related complications.